Development of 18 F-Labeled Positron Emission Tomography Agents Targeting Fibroblast Activation Protein
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.4c01235 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Liu Zhou und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medic…. Hauptthemen laut MEDLINE: Fluorine Radioisotopes, Positron-Emission Tomography, Membrane Proteins, Gelatinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Fibroblast activation protein (FAP) is expressed in activated fibroblasts but not in quiescent fibroblasts. Thus, it allows us to use this membrane-anchored enzyme as a target for radionuclide-based tumor diagnosis and treatment and the diagnosis of nonmalignant diseases. In this report, we synthesized and evaluated a series of 18F-labeled FAP inhibitors (FAPIs), aiming to obtain PET agents with good in vivo distribution and tumor specificity. These 18F-labeled arene- and aliphatic-vinyl sulfones were prepared with yields of 52.3-78.6%, which were then reacted with FAPIs to obtain corresponding imaging agents with yields of 47.3-88.7% (2nd step). When tested in the U87MG tumor-bearing mice, [18F]11 exhibited 8.2 ± 0.9%ID/g tumor uptake at 0.5 h p.i. with relatively low muscle uptake (T/M ratio of 10.5). In the presence of FAPI inhibitor SP-13786, the tumor uptake of [18F]11 was successfully reduced to 1.4%ID/g, confirming the receptor specificity of this agent. Autoradiography and immunohistochemical staining analysis revealed similar tumor distribution patterns of [18F]11 and FAP+ cells in U87MG tumor tissues. Our findings suggest that [18F]11 demonstrates great potential as an FAP-targeted PET agent for tumor detection and can be further evaluated in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646099, China.
- School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646608, China.
- Department of Radiology, Lineberger Comprehensive Cancer Center, and Biomedical Research Imaging Center, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Förderung
- Science and Technology Department of Sichuan Province
- National Natural Science Foundation of China
Zitieren
APA
Zhou, L., Sun, Q., Wang, C., Long, R., Hu, M., Wan, Q., Zhao, W., Joshi, S., Yang, L., Liu, H., Mao, Y., Yang, Y., Li, Z., Chen, Y., & Wang, L. (2025). Development of 18 F-Labeled Positron Emission Tomography Agents Targeting Fibroblast Activation Protein. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01235
Vancouver
Zhou L, Sun Q, Wang C, Long R, Hu M, Wan Q, et al. Development of 18 F-Labeled Positron Emission Tomography Agents Targeting Fibroblast Activation Protein. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01235
BibTeX
@article{Zhou2025,
author = {Zhou, Liu and Sun, Qinghong and Wang, Changjiang and Long, Ruiling and Hu, Mei and Wan, Qiang and Zhao, Weiling and Joshi, Sameer and Yang, Liping and Liu, Hao and Mao, Yifan and Yang, Yunyi and Li, Zibo and Chen, Yue and Wang, Li},
title = {Development of 18 F-Labeled Positron Emission Tomography Agents Targeting Fibroblast Activation Protein},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.4c01235}
}
EUVIMED